217 related articles for article (PubMed ID: 9614446)
1. Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology Group.
Kasai T; Ohe Y; Nishio K; Kunitoh H; Tamura T; Sekine I; Kubota K; Yamamoto N; Nakamura Y; Shinkai T; Kodama T; Saijo N
Jpn J Clin Oncol; 1998 Mar; 28(3):214-21. PubMed ID: 9614446
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
3. Problems with registration-directed clinical trials for lung cancer in Japan.
Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Saijo N; Tamura T
Tohoku J Exp Med; 2007 Sep; 213(1):17-23. PubMed ID: 17785949
[TBL] [Abstract][Full Text] [Related]
4. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.
Karim S; Xu Y; Kong S; Abdel-Rahman O; Quan ML; Cheung WY
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e160-e166. PubMed ID: 31133363
[TBL] [Abstract][Full Text] [Related]
5. Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group.
Kawahara M; Ariyoshi Y; Fukuoka M; Furuse K
Crit Rev Oncol Hematol; 2000 Oct; 36(1):9-12. PubMed ID: 10996519
[TBL] [Abstract][Full Text] [Related]
6. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
7. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
8. Development of cancer cooperative groups in Japan.
Fukuda H
Jpn J Clin Oncol; 2010 Sep; 40(9):881-90. PubMed ID: 20670961
[TBL] [Abstract][Full Text] [Related]
9. Eligibility of real-world patients with metastatic breast cancer for clinical trials.
Batra A; Kong S; Cheung WY
Breast; 2020 Dec; 54():171-178. PubMed ID: 33120082
[TBL] [Abstract][Full Text] [Related]
10. [Improving the infrastructure for clinical trials in Japan].
Nakano S
Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
[TBL] [Abstract][Full Text] [Related]
11. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
Statler A; Othus M; Erba HP; Chauncey TR; Radich JP; Coutre S; Advani A; Nand S; Ravandi F; Mukherjee S; Sekeres MA
Blood; 2018 Jun; 131(25):2782-2788. PubMed ID: 29618479
[TBL] [Abstract][Full Text] [Related]
12. Adherence to reporting guidelines and clinical trial registration policies in oncology journals: a cross-sectional review.
Wayant C; Moore G; Hoelscher M; Cook C; Vassar M
BMJ Evid Based Med; 2018 Jun; 23(3):104-110. PubMed ID: 29653939
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of staffing and infrastructures of paediatric oncology and haematology centres in Germany].
Herold R; Reiche R; Creutzig U; Henze G
Klin Padiatr; 2007; 219(6):380-90. PubMed ID: 18050051
[TBL] [Abstract][Full Text] [Related]
14. Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole.
Cottin V; Arpin D; Lasset C; Cordier JF; Brune J; Chauvin F; Trillet-Lenoir V
Ann Oncol; 1999 Jul; 10(7):809-15. PubMed ID: 10470428
[TBL] [Abstract][Full Text] [Related]
15. Quality assurance in clinical trials.
Ottevanger PB; Therasse P; van de Velde C; Bernier J; van Krieken H; Grol R; De Mulder P
Crit Rev Oncol Hematol; 2003 Sep; 47(3):213-35. PubMed ID: 12962897
[TBL] [Abstract][Full Text] [Related]
16. [Trends of lung cancer incidence and its prognosis in Osaka, Japan].
Hanai A; Sobue T; Tsukuma H; Hiyama T; Fujimoto I
Gan To Kagaku Ryoho; 1994 May; 21(6):727-35. PubMed ID: 8185326
[TBL] [Abstract][Full Text] [Related]
17. Compliance with Good Clinical Practice in oncology registration trials in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Ann Oncol; 2011 Jun; 22(6):1451-1456. PubMed ID: 21119030
[TBL] [Abstract][Full Text] [Related]
18. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
19. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
20. When are clinical trials registered? An analysis of prospective versus retrospective registration.
Harriman SL; Patel J
Trials; 2016 Apr; 17():187. PubMed ID: 27079379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
